Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma

Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCI Insight
Egile Nagusiak: Imai, Yoichi, Ohta, Eri, Takeda, Shu, Sunamura, Satoko, Ishibashi, Mariko, Tamura, Hideto, Wang, Yan-hua, Deguchi, Atsuko, Tanaka, Junji, Maru, Yoshiro, Motoji, Toshiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2016
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/
https://ncbi.nlm.nih.gov/pubmed/27699258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak